Search Results - "García‐Navarro, X."

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria by Curto‐Barredo, L., Spertino, J., Figueras‐Nart, I., Expósito‐Serrano, V., Guilabert, A., Melé‐Ninot, G., Cubiró, X., Bonfill‐Ortí, M., Garcias‐Ladaria, J., Villar, M., García‐Navarro, X., Bielsa‐Marsol, I., Vilavella, M., Aparicio, G., Baliu‐Piqué, C., Álvarez, A., Lamas‐Domenech, N., Duran‐Jordà, X., Serra‐Baldrich, E., Giménez‐Arnau, A.

Get full text

Adherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasis by Vidal, D., Salleras, M., Romaní, J., Ribera, M., Gallardo, F., Viñas, M., Xifra, A., García-Navarro, X., Bordas, X., Ferran, M., Carrascosa, J.M.

Get full text

Spanish Consensus Document on the Treatment Algorithm for Rosacea by Salleras, M, Alegre, M, Alonso-Usero, V, Boixeda, P, Domínguez-Silva, J, Fernández-Herrera, J, García-Navarro, X, Jiménez, N, Llamas, M, Nadal, C, Del Pozo-Losada, J, Querol, I, Salgüero, I, Schaller, M, Soto de Delás, J

Get full text

Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice by Puig, L., Roé, E., García-Navarro, X., Corella, F., Alomar, A.

“…Summary Background.  Efalizumab is approved by the European Medicines Evaluation Agency for the treatment of adult patients with moderate to severe plaque…”
Get full text

Acute generalized skin eruption due to adalimumab: report of two cases by Dalmau, J, Roé, E, Corella, F, García-Navarro, X, Peramiquel, L, Alomar, A

Get full text

Cutaneous vasculitis associated with gemcitabine therapy by Corella, F., Dalmau, J., Roé, E., García-Navarro, X., Alomar, A.

Get full text

A case of vulvar pyoderma gangrenosum associated with collagenous colitis by Roé, E, Dalmau, J, García-Navarro, X, Corella, F, Monfort, D, Busquets, D, Ribé, A, Delgado, E, Alomar, A

“…Pyoderma gangrenosum is a reactive inflammatory dermatosis which belongs to the spectrum of neutrophilic dermatoses. Due to a lack of diagnostic criteria,…”
Get more information

Definition of Recurrent Chronic Spontaneous Urticaria by Melé-Ninot, G, Serra-Baldrich, E, Curto-Barredo, L, Figueras-Nart, I, Spertino, J, Expósito-Serrano, V, García-Navarro, X, Guilabert, A, Bielsa-Marsol, I, Giménez-Arnau, A

“…Abstract is missing (Short communication)…”
Get full text

Spanish Consensus Document on the Treatment Algorithm for Rosacea by Salleras, M., Alegre, M., Alonso-Usero, V., Boixeda, P., Domínguez-Silva, J., Fernández-Herrera, J., García-Navarro, X., Jiménez, N., Llamas, M., Nadal, C., del Pozo-Losada, J., Querol, I., Salgüero, I., Schaller, M., Soto de Delás, J.

“…Recent scientific evidence and the incorporation of new drugs into the therapeutic arsenal against rosacea have made it necessary to review and update…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J, Curto Barredo, L, Rozas Muñoz, E, Figueras Nart, I, Gimenez Arnau, A, Serra Baldrich, E, Bonfill-Ortí, M, Expósito-Serrano, V, Guilabert, A, Melé Ninot, G, Villar Buil, M, Garcias Ladaria, J, García Navarro, X, Vilavella, M, Bielsa Marsol, I, Aparicio Ortiz, G, Baliu Piqué, C, Álvarez Abella, A, Lamas Domenech, N, Mascaró, J M, Gómez, S, Torné Gutiérrez, J I, Vicente Villa, A

“…BACKGROUND AND OBJECTIVEPivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in…”
Get full text

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab by Spertino, J., Curto Barredo, L., Rozas Muñoz, E., Figueras Nart, I., Serra Baldrich, E., Bonfill-Ortí, M., Expósito-Serrano, V., Guilabert, A., Melé Ninot, G., Villar Buil, M., Garcias Ladaria, J., García Navarro, X., Vilavella, M., Bielsa Marsol, I., Aparicio Ortiz, G., Baliu Piqué, C., Álvarez Abella, A., Lamas Domenech, N., Mascaró, J.M., Gómez, S., Torné Gutiérrez, J.I., Vicente Villa, A., Gimenez Arnau, A.

“…Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many…”
Get full text

Bortezomib-associated cutaneous vasculitis by Garcia-Navarro, X., Puig, L., Fernández-Figueras, M.T., Dalmau, J., Roe, E., Alomar, A.

Get full text

Mycobacterium abscessus infection secondary to mesotherapy by Garcia-Navarro, X., Barnadas, M. A., Dalmau, J., Coll, P., Gurguí, M., Alomar, A.

Get full text

Tacrolimus in diseases other than atopic dermatitis by Alomar, A, Corella, F, García-Navarro, X

“…Topical tacrolimus is an immunosuppressant that acts through the inhibition of calcineurin and thus of the T cells. This causes a decrease in the production of…”
Get full text

Systemic Cryptococcosis Presenting as Extensive Cellulitis in a Patient With Rheumatoid Arthritis by Diaz-Sarrió, C., García-Navarro, X., Claver-Cercós, G., Baucells-Azcona, J.M., Martín-Plata, C., Corcoy-Grabalosa, M.

Get full text

Tacrolimus in diseases other than atopic dermatitis by Alomar, A, Corella, F, García-Navarro, X

Get full text

Systemic cryptococcosis presenting as extensive cellulitis in a patient with rheumatoid arthritis by Diaz-Sarrió, C, García-Navarro, X, Claver-Cercós, G, Baucells-Azcona, J M, Martín-Plata, C, Corcoy-Grabalosa, M

Get full text